Valneva (VALN) to Release Earnings on Wednesday

Valneva (NASDAQ:VALN) is anticipated to release its earnings data before the market opens on Wednesday, March 19th. Analysts expect Valneva to post earnings of ($0.22) per share and revenue of $55.64 million for the quarter.

Valneva Trading Up 0.1 %

VALN opened at $6.80 on Monday. The business has a 50 day simple moving average of $6.11 and a two-hundred day simple moving average of $5.60. The firm has a market capitalization of $552.57 million, a price-to-earnings ratio of -52.31 and a beta of 1.93. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25. Valneva has a one year low of $3.62 and a one year high of $9.50.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $17.00 price target on shares of Valneva in a research report on Friday, February 28th.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.